TIRZEPATIDE 10MG

"A dual GIP/GLP-1 receptor agonist that researchers study for its effects on glycemic control and body weight management — simultaneously activating two incretin pathways that most compounds only touch one of."

What It Is

Tirzepatide is a synthetic 39-amino-acid peptide derived from the native GIP sequence. Developed by Eli Lilly, it was engineered to activate both the GIP receptor and the GLP-1 receptor simultaneously — a dual-agonist approach that no prior incretin-based compound had achieved.

Unlike single-target GLP-1 agonists, tirzepatide's dual mechanism engages two complementary pathways involved in insulin secretion, appetite regulation, and gastric emptying.

How It Works

GLP-1R — Suppresses appetite at the hypothalamus, slows gastric emptying, stimulates glucose-dependent insulin release.

GIP-R — Amplifies insulin secretion and enhances lipolysis signaling in adipose tissue.

When both receptors are activated together, the effects stack — appetite suppression plus enhanced fat metabolism signaling create a synergy that neither pathway produces alone.

What the Research Shows

Why Choice

• ✅ Lab-tested — every batch with third-party COA
• ✅ Made for researchers — research-use-only, no medical claims
• ✅ American-shipped — Florida fulfillment, USPS Priority
• ✅ Premium presentation — gold-swirl vial, sealed, labeled

Certificate of Analysis

Every vial ships with a COA. View the full library for batch-specific HPLC purity, content accuracy, and endotoxin data.

Stacks With

Tirzepatide research pairs well with:

Frequently Asked Questions